THERAPEUTIC ACTIVATION OF IMMUNOGENIC CELL DEATH TO IMPROVE IMMUNOTHERAPY FOR KIDNEY CANCER

$1,062,000FY2022Defense Health AgencyDOD

Sloan-Kettering Institute For Cancer Research

Investigators